refractory advanced SCCHN, CRC, HNSCC, melanoma and HER2+ breast cancer; alone or combined with cetuximab, erlotinib, vemurafenib and trastuzumab. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.